US FDA’s Patient Input Guidance Opens Door Wider To Social Media Data Collection

Following stakeholder criticism of an earlier discussion paper, draft guidance does not automatically foreclose use of social media data as the primary source of qualitative research; however, agency says entities submitting such data for regulatory review must ensure rigor in methodology and data integrity.

KIEV, UKRAINE - MAY 18, 2015:Collection of popular social media logos printed on paper:Facebook, Twitter, Google Plus, Instagram, Skype, WhatsApp, Pinterest, Blogger and others on white background

The US FDA appears to have had a change of heart when it comes to using social media to collect patient experience data.

The agency takes a more open and flexible view on the use of social media data collection methods in a new draft guidance on collecting comprehensive and representative patient...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D